Ready to turn a new page, Landos Biopharma offloads former lead program to founder

Amber Tong

Earlier this year, autoimmune-focused biotech Landos Biopharma announced that following a review of its pipeline, it will concentrate on one of its clinical programs and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ready to turn a new page, Landos Biopharma offloads former lead program to founder

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ready to turn a new page, Lan­dos Bio­phar­ma of­floads for­mer lead pro­gram to founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ready to turn a new page, Landos Biopharma offloads former lead program to founder